Objectives: 
Prostate specific membrane antigen (PSMA) is a highly overexpressed cell surface glycoprotein in prostate cancer (1) (2) (3) . 68 Ga-labeled urea-based small molecules that bind with high affinity to the extracellular domain of PSMA, such as 68 Ga-HBED-PSMA-11, have rapidly emerged as a disruptive technology for imaging prostate cancer (4) (5) (6) . Positron emission tomography (PET) with 68 Ga-HBED-PSMA-11 produces high tumor-to-background contrast and has been rapidly adopted in jurisdictions where the regulatory environment enables on-site, extemporaneously compounded radiotracers to be adopted in the clinic. In other jurisdictions, differing regulatory requirements has limited adoption of PSMA PET. Routine clinical cGMP production of 68 Ga-HBED-PSMA11 is limited by synthesis time, and the need for an expensive automated synthesis device and onsite radiochemistry expertise. 68 Ga-HBED-PSMA-11 PET/CT has demonstrated clinical utility in both initial staging of newly diagnosed patients and restaging patients in the setting of biochemical recurrence and has rapidly emerged as a practice-changing modality for imaging prostate cancer. More accurate staging of high-risk patients may enable better selection of the most appropriate management strategy and avoid futile locoregional surgery or radiotherapy in patients with metastatic disease. For staging, several studies have demonstrated high sensitivity compared to conventional imaging (7) (8) (9) (10) . In the setting of early biochemical recurrence, PSMA PET/CT has high sensitivity even in patients with PSA below 1.0 ng/ml where conventional imaging is invariably unhelpful (11) . PSMA PET/CT can have a consequent high management impact in these patients (12) .
A new radiopharmaceutical, 68 Ga-THP-PSMA, for the same diagnostic purpose as 68 Ga-HBED-PSMA-11 but designed for greatly simplified one-step kit-based radiolabeling, has been developed (13) Ga-HBED-PSMA-11 (13) . Ga-THP-PSMA can be safely administered, and (2) its biodistribution will facilitate specific and sensitive identification of PSMA-expressing malignant tissues using PET/CT, with an acceptable absorbed radiation dose.
MATERIALS AND METHODS
This investigator-initiated prospective study was sponsored by the Peter MacCallum Cancer Centre, and ethically approved by the institutional review board. It was prospectively registered (Australian New Zealand Clinical Trials Registry No 12615001324505). All subjects gave informed consent.
Fourteen patients with biopsy proven adenocarcinoma of the prostate were recruited; eight in Group A and six in Group B. Safety and biodistribution of 68 Ga-THP-PSMA were assessed in all patients. In Group A, additional aims were to define whole body radiation dose and plasma radiotracer clearance, and correlate uptake with tumor PSMA expression on histopathology. In Group B, the aim was to compare physiologic and pathologic biodistribution in patients with PSMA-avid malignant disease on 68 Ga-HBED-PSMA-11 PET/CT.
In Group A, patients had no prior treatment for prostate carcinoma and were scheduled for prostatectomy.
They underwent multiple whole body PET/CT scans as detailed below to determine biodistribution and dosimetry of 68 Ga-THP-PSMA. Regions of interest were drawn around standard organs and intensity of uptake measured using SUVmax. Absorbed organ and whole body doses were determined by calculation of time activity values for standard organs using OLINDA/EXM version 1.1 (14).
A positive scan was defined by visual analysis if there was uptake in the prostate above background and was localised using a 4-segment prostate model. Intensity of uptake was measured using SUVmax. Nodal or distant metastases were identified by visual interpretation.
All Group A patients proceeded to prostatectomy. Samples were fixed in formalin and handled as per routine practice. 3 µm sections cut from paraffin blocks containing tumor were immunohistochemically stained for PSMA (Dako (Agilent) clone 3E6, 1:100 dilution) using a Ventana Benchmark Ultra automated stainer, with incubation period 32 minutes, high-pH epitope-retrieval buffer using Ventana CC1 solution for 40 minutes, and detection using the Ventana Optiview Detection kit (DAB based). 
RESULTS
Fourteen patients were screened and all proceeded to study participation and completion. No adverse events attributed to 68 Ga-THP-PSMA administration were recorded in any of the patients.
Group A. Baseline cohort characteristics and results are summarized in Table 1 . Six of eight patients had increased uptake in the prostate above background. SUVmax of dominant prostate abnormality was 5.1 (range 2.4 -9.2) at 120 minutes. The earlier time-point acquisitions acquired for purposes of dosimetry calculation were not suitable for determination of prostate uptake, owing to single CT acquisition at 0 minutes and subsequent bladder filling resulting in attenuation correction artefact in the surrounding pelvis.
Physiologic uptake was seen in lacrimal glands, salivary glands, liver, spleen and duodenum. The intensity of uptake in these organs was low (see Table 2 ). High kidney, ureteric and bladder activity was seen owing to renal excretion.
The mean effective dose was 2.07E-02 mSv/MBq (see Table 3 ). As patients were asked not to void during the imaging period and bladder accumulation occurs, this represents an overestimate to routine clinical practice. Plasma clearance was measured in 7 patients; technical difficulties obviated measurement in one. Findings were consistent with all patients demonstrating 2-phase exponential clearance with a mean of 5.9 minute (range 2.6 -8.4) first phase half-time followed by 91.1 minute (range 67.2 -118.5) second phase clearance (see Figure 2 ).
All patients proceeded to prostatectomy. 3+ intensity PSMA immunohistochemistry staining was seen in 6 THP-PSMA positive scans, and 1+ / 2+ staining in the 2 THP-PSMA negative scans (Figure 3) . Seven of eight underwent pelvic nodal dissection. Pathologic pelvic nodal involvement was identified in 2 patients without corresponding 68 Ga-THP-PSMA abnormality, although these were both <1 mm in size, well below imaging resolution. One patient had focal intense uptake in sub-cm pelvic nodes without pathologic abnormality. Follow-up at 6 months confirmed accuracy of initial 68 Ga-HBED-PSMA11 and contrast-enhanced CT confirming nodal progression (see Figure   4 ).
Group B

68
Ga-THP-PSMA with imaging at 60 minutes had lower background physiologic uptake in salivary glands, liver and spleen compared to 68 Ga-HBED-PSMA-11 (parotid: mean SUVmax 3.6 compared to 19.2, p<0.001; liver: 2.7 compared to 6.3, p<0.001; spleen 2.7 compared to 10.5, p<0.001). In all 6 patients, metastatic lesions were identified on both HBED-and THP-PSMA (Table 3, Figure 5 
DISCUSSION
In this study, we provide the first-in-man validation of 68 Ga-THP-PSMA, the first clinical tracer to utilize the novel THP chelator, enabling labelling in less than five minutes at room temperature. The DOTA chelator, incorporated in the widely used DOTATATE, requires pH adjustment, heating followed by cooling, and sometimes a purification step, necessitating either significant manual handling or use of an by King's College London on October 10, 2017. For personal use only. jnm.snmjournals.org Downloaded from automated synthesis device. This increases expense and may not be compliant with Good Manufacturing Practice (GMP). Moreover, cartridge-based automated synthesis typically takes more than 30 minutes, which is suboptimal for a short-life radionuclide such as 68 Ga. HBED chelation can be performed at room temperature but this produces a mixture of cis/trans geometric isomers (5) . Recently, favourable labelling properties for the DATA chelator for labelling DATATOC in a kit formulation have been described (15) .
THP-PSMA has been developed as a single step kit-formulated GMP radiopharmaceutical, requiring only addition of unprocessed, unfractioned generator eluate to a single vial. Depending on the generator used, however, additional simple steps may be required. The one step kit can also be used with generators with <0.001% 68 Ge breakthrough and appropriate elution volume, such as the GalliaPharm Generator from Eckert and Ziegler (7). 68 Ga-THP-PSMA imparts low absorbed doses, with effective doses similar to those published for 68 Ga-HBED-PSMA-11 (16) . In this study a mean effective dose of 4.9 mSv was observed. Recently published Ga-THP-PSMA had significantly lower background physiologic uptake compared to 68 Ga-HBED-PSMA-11. Specifically, salivary and tear glands (lacrimal, parotid and submandibular), liver and small bowel uptake was significantly lower. The mechanism of uptake in salivary glands remains uncertain perhaps reflecting non-specific radiotracer excretion, PSMA expression in these tissues or an unknown target with similar recognition properties. As there is no known expression of PSMA in the liver or spleen, the differential uptake possibly reflects particulate radioactivity with 
